Skip to main content

Table 3 Summary of multivariate Cox proportional hazards regression analysis of effect of BMI and each study variable on overall mortality, breast cancer mortality, and recurrence in full models

From: Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

  Overall mortality Breast cancer mortality Recurrence
Variable HRa 95% CI P -value HR 95% CI P -value HR 95% CI P -value
Body mass index, k/m2          
<18.5 0.98 0.53, 1.79 0.945 0.95 0.48, 1.85 0.871 0.77 0.43, 1.37 0.377
18.5 to 24.9 1.00    1.00    1.00   
25.0 to 29.9 0.95 0.80, 1.12 0.549 1.01 0.84, 1.22 0.905 1.03 0.89, 1.19 0.728
30.0 to 34.9 0.98 0.79, 1.20 0.814 1.02 0.81, 1.29 0.860 1.07 0.89, 1.29 0.460
≥35 1.35 1.06, 1.72 0.016 1.32 1.00, 1.74 0.053 1.25 0.99, 1.57 0.052
Age          
Per 5 years 0.92 0.87, 0.97 0.003 0.86 0.81, 0.92 <0.001 0.84 0. 80, 0.89 <0.001
Menopausal status          
Postmenopausal 1.00    1.00    1.00   
Premenopausal 0.60 0.48, 0.74 <0.001 0.56 0.44, 0.71 <0.001 0.64 0.53, 0.77 <0.001
Pathologic primary tumor size          
T1 1.00    1.00    1.00   
T2 1.82 1.56, 2.32 <0.001 1.87 1.57, 2.22 <0.001 1.67 1.46, 1.91 <0.001
T3 1.88 1.40, 2.53 <0.001 2.07 1.51, 2.84 <0.001 1.71 1.31, 2.23 <0.001
Histological grade          
1 1.00    1.00    1.00   
2, 3, or unknown 1.26 1.07, 1.48 0.006 1.32 1.10, 1.58 0.003 1.24 1.07, 1.43 0.004
Type of surgery          
Mastectomy 1.00    1.00    1.00   
Conservative 0.82 0.70, 0.95 0.008 0.83 0.70, 0.98 0.028 0.84 0.74, 0.96 0.011
Estrogen receptor/progesterone receptor          
Both negative 1.00    1.00    1.00   
Any positive 0.56 0.48, 0.64 <0.001 0.51 0.44, 0.60 <0.001 0.66 0.57, 0.75 <0.001
Unknown 0.85 0.51, 1.44 0.558 0.89 0.52, 1.54 0.689 1.10 0.69, 1.75 0.699
Human epidermal growth factor-2 status          
Negative 1.00    1.00    1.00   
Positive 1.19 1.00, 1.42 0.048 1.23 1.01, 1.49 0.037 1.23 1.05, 1.44 0.009
Unknown 1.00 0.82, 1.23 0.965 1.11 0.89, 1.38 0.361 1.09 0.91, 1.30 0.335
Undertreatment          
None 1.00    1.00    1.00   
Epirubicine <85% 2.36 1.18, 4.72 0.015 3.06 1.47, 6.36 0.003 1.84 0.93, 3.63 0.078
Cyclophosph <85% 0.86 0.35, 2.13 0.74 0.93 0.34, 2.53 0.880 1.31 0.58, 2.95 0.519
Fluorouracil <85% 0.64 0.30, 1.34 0.235 0.45 0.19, 1.07 0.069 0.50 0.26, 0.99 0.046
Doxorubicin <85% 1.86 0.89, 3.88 0.097 1.86 0.82, 4.22 0.134 1.29 0.63, 2.64 0.478
Docetaxel <85% 0.84 0.46, 1.53 0.559 0.70 0.35, 1.40 0.315 0.75 0.44, 1.28 0.294
Paclitaxel <85% 1.37 0.90, 2.09 0.147 1.06 0.62, 1.81 0.824 1.15 0.78, 1.70 0.491
  1. Models were adjusted for all the other variables in the table. aHazard ratio, 95% CI and P-value adjusted for study, treatment regimen and the rest of variables in the table.